• 24 July 2008

    Santhera Pharmaceuticals (SWX:SANN), a Swiss specialty pharmaceutical company focused on neuromuscular diseases, announced today that Health Canada has approved with conditions SNT-MC17/idebenone for the treatment of Friedreich's Ataxia. Health Canada's decision is the first marketing authorization worldwide for any Friedreich's Ataxia therapy. The new drug will be marketed in Canada under the brand name Catena®. Santhera has established a wholly owned Canadian subsidiary, Santhera Pharmaceuticals (Canada), Inc. recently incorporated in Montréal, Quebec, to address the needs of Canada's several hundred patients with this rare and severely progressive muscle disease. Launch of Catena is anticipated for the end of October 2008.

  • 11 August 2008

    Kuros Biosurgery AG announced today the results of the one-month follow-up of a Phase IIa clinical trial assessing the potential of KUR-212 (Viz.I-020502), its novel platelet-derived growth factor (PDGF) and fibrin combination product, for the treatment of patients with burns requiring autologous meshed skin grafting. In the one-month follow-up of this Phase IIa study, there were no treatment-related adverse events, meeting the primary endpoint (safety) of the study.

  • 6 June 2008

    CREABILIS therapeutics SpA, an emerging specialty pharmaceutical company focused on dermatology, today announces that it has raised a total of €20 million in a Series A round of funding. The financing was led by Sofinnova Partners, which was joined in the funding round by NeoMed Management. Representatives of both Sofinnova and NeoMed will be joining the CREABILIS therapeutics's Board following this fund raising.

  • 9 May 2008

    EUSA Pharma announced today that it has completed its acquisition of Cytogen Corporation, following the approval of Cytogen’s shareholders at a special meeting on 8 May.

  • 18 February 2008

    EUSA Pharma today today announced that it has out-licensed the exclusive world-wide rights to its preclinical-stage human anti-interleukin-6 antibody to GlaxoSmithKline (GSK) for a consideration of up to $44 million, comprising an upfront fee and development milestones, plus royalties on future sales. As part of the agreement EUSA will pay approximately 50% of the overall consideration to its development partner for the antibody, Vaccinex Inc. GSK will fund and conduct all future development, production and commercialization of the product.